Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. (2021)

First Author: Gorman E
Attributed to:  A GMP cell therapy facility to test cell based therapies funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1080/17476348.2021.1848555

PubMed Identifier: 33172313

Publication URI: http://europepmc.org/abstract/MED/33172313

Type: Journal Article/Review

Volume: 15

Parent Publication: Expert review of respiratory medicine

Issue: 3

ISSN: 1747-6348